Buy Tamoxifen powder (10540-29-1) hplc≥98% – β-Agonist Wisepowder
Chemical Base Information
Chemical name (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine
Synonyms TMX; ICI-46474
Molecular Formula C26H29NO
Molecular Weight 371.51
Melting Point >92°C (dec.)
InChI Key NKANXQFJJICGDU-QPLCGJKRSA-N
Appearance White to Off-White
Half Life 5 to 7 days
Solubility Chloroform (Sparingly), Methanol (Slightly)
Storage Condition 2-8°C
Application It’s applied to the treatment of advanced, recurrent breast cancer and ovarian cancer.
Testing Document Available
03 Tamoxifen (10540-29-1) General Description
Tamoxifen powder is an antagonist of the estrogen receptor in breast tissue via its active metabolite, 4-hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a selective estrogen-receptor modulator. Tamoxifen is the usual endocrine (anti-estrogen) therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting.
Some breast cancer cells require estrogen to grow. Estrogen binds to and activates the estrogen receptor in these cells. Tamoxifen is metabolized into compounds that also bind to the estrogen receptor but do not activate it. Because of this competitive antagonism, tamoxifen acts like a key broken off in the lock that prevents any other key from being inserted, preventing estrogen from binding to its receptor, blocking cancer cell growth.
Tamoxifen was discovered by pharmaceutical company Imperial Chemical Industries(now AstraZeneca) and is sold under the trade names Nolvadex, Istubal, Valodex, and Genox. However, the drug has been widely referred to by its generic name “tamoxifen”, even before its patent expiration.
It is on the World Health Organization’s List of Essential Medicines, a list of the most important medication needed in a basic health system.
04 Tamoxifen (10540-29-1) History
Tamoxifen was initially made in 1962 by chemist Dora Richardson. It is on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system. Tamoxifen is available as a generic medication. Tamoxifen is one of three drugs in an anti-angiogenetic protocol developed by Dr. Judah Folkman, a researcher at Children’s Hospital at Harvard Medical School in Boston. Folkman discovered in the 1970s that angiogenesis – the growth of new blood vessels – plays a significant role in the development of cancer. Since his discovery, an entirely new field of cancer research has developed. Clinical trials on angiogenesis inhibitors have been underway since 1992 using many different drugs. The Harvard researchers developed a specific protocol for a golden retriever named Navy who was cancer-free after receiving the prescribed cocktail of celecoxib, doxycycline, and tamoxifen – the treatment subsequently became known as the Navy Protocol. Furthermore, tamoxifen treatment alone has been shown to have anti-angiogenetic effects in animal models of cancer which appear to be, at least in part, independent of tamoxifen’s ER antagonist properties.